PT Itama Ranoraya (IRRA) Fundamentals 2026 — P/E 8.5x, Revenue Analysis | SniperIQ
PT Itama Ranoraya (IRRA) is a ID-listed Healthcare company in Medical - Distribution with a market capitalization of Rp557.9B, trading at Rp370.00 on the JKT. This SniperIQ fundamentals page covers PT Itama Ranoraya's valuation (P/E 8.5x, P/B 1.0x), profitability (net margin 6.0%), revenue (Rp1.10T in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is PT Itama Ranoraya's market cap?
PT Itama Ranoraya (IRRA) has a market capitalization of approximately Rp557.9B, trading at Rp370.00 on the JKT. Market cap moves with the live share price.
What is PT Itama Ranoraya's P/E ratio?
PT Itama Ranoraya's trailing twelve-month P/E ratio is 8.5x, with a price-to-book (P/B) of 1.0x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is PT Itama Ranoraya?
PT Itama Ranoraya runs a net profit margin of 6.0%, a gross margin of 23.6%, and an operating margin of 10.2%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does PT Itama Ranoraya generate?
PT Itama Ranoraya reported revenue of Rp1.10T for fiscal year 2025, with net income of Rp65.5B and earnings per share (EPS) of 42.44. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does PT Itama Ranoraya pay a dividend?
PT Itama Ranoraya does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is PT Itama Ranoraya financially healthy?
PT Itama Ranoraya carries a debt-to-equity ratio of 1.68x and a current ratio of 1.41x, with a market beta of 0.34. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is PT Itama Ranoraya a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For PT Itama Ranoraya (IRRA) the key facts are: market cap Rp557.9B, P/E 8.5x, revenue Rp1.10T, 52-week range 322-615. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track PT Itama Ranoraya's full fundamentals live
Get PT Itama Ranoraya's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.